The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

A. Heres Diddens; S. Kraaijenga; V. Coupé; F. Hilgers; L. van der Molen; L. Smeele; V.P. Retèl

doi:10.1080/08869634.2016.1232344

The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

A. Heres Diddens, S. Kraaijenga, V. Coupé, F. Hilgers, L. van der Molen, L. Smeele, V.P. Retèl

Maxillofacial Surgery (AMC)

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.

Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.

Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.

Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.

Original language	English
Pages (from-to)	290-297
Journal	CRANIO
Volume	35
Issue number	5
DOIs	https://doi.org/10.1080/08869634.2016.1232344
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/08869634.2016.1232344

Persistent URL (handle)

Copy link address

Cite this

@article{c5c18bd953c04b89b7d88982427a10f9,

title = "The cost-effectiveness of TheraBite{\textregistered} as treatment for acute myogenic temporomandibular disorder",

abstract = "Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite{\textregistered} (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.",

author = "{Heres Diddens}, A. and S. Kraaijenga and V. Coup{\'e} and F. Hilgers and {van der Molen}, L. and L. Smeele and V.P. Ret{\`e}l",

year = "2017",

doi = "10.1080/08869634.2016.1232344",

language = "English",

volume = "35",

pages = "290--297",

journal = "CRANIO",

issn = "0886-9634",

publisher = "Chroma, Inc.",

number = "5",

}

TY - JOUR

T1 - The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

AU - Heres Diddens, A.

AU - Kraaijenga, S.

AU - Coupé, V.

AU - Hilgers, F.

AU - van der Molen, L.

AU - Smeele, L.

AU - Retèl, V.P.

PY - 2017

Y1 - 2017

N2 - Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.

AB - Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.

U2 - 10.1080/08869634.2016.1232344

DO - 10.1080/08869634.2016.1232344

M3 - Article

SN - 0886-9634

VL - 35

SP - 290

EP - 297

JO - CRANIO

JF - CRANIO

IS - 5

ER -

The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this